Response to treatment with metformin in patients with polycystic ovarian syndrome: territorial center of care for the infertile couple, Holguín
- Pharmacy & Pharmacology International Journal
-
Annis Almenares Garcés,1 Leandro León Román,2 Yisell González Ríos,3 Maurio González Hernández,4 Annarelis Pérez Pupo,5 Aylen Pérez Almenares6
Second degree specialist in Comprehensive General Medicine, First Degree in Endocrinology, Assistant teacher, Vladimir Ilich Lenin University General Hospital, Cuba, Second Degree Specialist in Allergology, Máximo Gómez Báez Polyclinic, Cuba, First degree specialist in Comprehensive General Medicine and Endocrinology, Assistant teacher, Amalia Simoni Argilagos University General Hospital, Cuba, First degree specialist in Comprehensive General Medicine and Endocrinology, Instructor teacher, Holguin Military Hospital, Cuba, Degree in Health Information Management, Assistant teacher, Vladimir Ilich Lenin University General Hospital, Cuba, General practitioner, Manuel Díaz Legra Polyclinic, Cuba
Abstract
Introduction: Approximately 60% of women with polycystic ovarian syndrome are overweight and obese, 70% have insulin resistance and type 2 diabetes mellitus. The global prevalence of gestational diabetes mellitus is estimated at 14%.
Objective: To evaluate the response to metformin treatment in patients with polycystic ovarian syndrome.
Method: A retrospective case series study was conducted, which involved 96 patients diagnosed with polycystic ovarian syndrome treated at the Territorial Center for Infertile Couple Care, selected within a non-probabilistic sample, to which comprehensive evaluation was performed. Initial that included physical examination and complementary, then it was indicated as part of the medical treatment metformin (500mg tablet) in increasing doses of 500 to 1000mg, according to patient tolerances for a period of six months. After this period of time, a humoral clinical evaluation was carried out which allowed determining the group of patients suitable for ovulation stimulation, which coincided with the total sample.
Results: Of 96 patients who formed the sample and received treatment with metformin, more than 50% were between 25 and 34 years old. 78.7% showed a decrease in hyperandrogenism, (66.18%) patients achieved pregnancy and only 48, 89% showed manifestations of gestational diabetes.
Conclusions: Metformin is a useful drug for the treatment of polycystic ovarian syndrome as a cause of female infertility. Its regular use helps to reduce the incidence of gestational diabetes and the complications derived from this disease.
Keywords
polycystic ovary syndrome, gestational diabetes, metformin
